Proskauer Advises Celgene Corporation in Its Acquisition of Juno Therapeutics
Jan 22, 2018 - Business Wire
International law firm Proskauer represented longtime client Celgene Corporation (NASDAQ: CELG) in its definitive agreement to acquire Juno Therapeutics, Inc. (NASDAQ: JUNO). Under the terms of the merger agreement, Celgene will pay $87 per share in cash, or a total of approximately $9 billion, net of cash and marketable securities acquired and Juno shares already owned by Celgene (approximately 9.7% of outstanding shares).
Juno is a pioneer in the development of CAR (chimeric antigen rece...
Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.
Are you ready to take your business development to the next level with RelSci Professional?
Nurture your network with daily alerts that notify you when your relationships make news
Map your relationships to any target or prospect to identify a warm introduction
Access unlimited deep dossiers on over 8 million decision makers
Best of all, you can try out all these powerful business development tools absolutely free for 30 days!
Check out News Home to stay on top of the people and organizations you care most about.
